UPDATED Mar 07, 2024
Investing in companies that think about the future will generate eco-friendly products and sustainable returns. As consumers become more environmentally-aware, demand will increase for these companies' products.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
CAPRCapricor Therapeutics | US$5.04 | 10.4% | 8.6% | US$157.0m | US$18.75 | PS6.2x | E59.1% | n/a | ||
CKPTCheckpoint Therapeutics | US$2.17 | -2.7% | -48.3% | US$80.7m | US$18.25 | PS471.9x | E80.4% | n/a | ||
SRPTSarepta Therapeutics | US$120.78 | -6.1% | -16.1% | US$11.3b | US$164.42 | PS9.1x | E41.8% | n/a | ||
SPRYARS Pharmaceuticals | US$8.95 | 2.8% | 13.9% | US$859.2m | US$18.50 | PS28639.2x | E49.8% | n/a | ||
ACADACADIA Pharmaceuticals | US$23.52 | -2.0% | 15.5% | US$3.9b | US$33.50 | PS5.3x | E46.0% | n/a | ||
PGENPrecigen | US$1.67 | -1.2% | 53.2% | US$415.7m | US$8.95 | PS61.5x | E48.2% | n/a | ||
TBPHTheravance Biopharma | US$8.69 | -7.9% | -15.0% | US$418.6m | US$14.00 | PS7.3x | E56.8% | n/a | ||
ETONEton Pharmaceuticals | US$4.49 | 0.7% | 16.0% | US$115.2m | US$10.00 | PE51.6x | E21.0% | n/a | ||
BFRIBiofrontera | US$1.19 | 33.4% | -89.3% | US$6.1m | US$16.00 | PB5.8x | E62.3% | n/a | ||
CYCCCyclacel Pharmaceuticals | US$2.49 | -14.1% | -74.6% | US$3.3m | US$163.00 | PS8.4x | E52.2% | n/a | ||
CRMDCorMedix | US$3.62 | -1.4% | -3.2% | US$198.3m | US$13.25 | PS6677.7x | E58.6% | n/a | ||
MDWDMediWound | US$16.92 | 19.2% | 56.7% | US$156.0m | US$28.50 | PS6.2x | E56.9% | n/a | ||
SPPISpectrum Pharmaceuticals | US$1.03 | 5.3% | 17.0% | US$209.9m | US$1.26 | PS8.2x | E67.3% | n/a | ||
SBFMSunshine Biopharma | US$0.061 | 9.6% | -93.0% | US$3.3m | US$3.00 | PB0.2x | E127.4% | n/a | ||
PRPHProPhase Labs | US$4.72 | 3.5% | -28.7% | US$85.2m | US$15.50 | PS1.4x | E75.3% | 6.4% | ||
VRCAVerrica Pharmaceuticals | US$4.86 | -12.4% | -25.9% | US$206.2m | US$13.60 | PS40.2x | E62.0% | n/a | ||
NBIXNeurocrine Biosciences | US$135.33 | 3.1% | 41.2% | US$13.5b | US$150.36 | PE53.9x | E26.5% | n/a | ||
INCYIncyte | US$59.03 | -0.03% | -18.0% | US$13.3b | US$75.82 | PE22.2x | E20.2% | n/a | ||
IVVDInvivyd | US$3.81 | -6.4% | 115.3% | US$452.8m | US$7.67 | PB1.8x | E57.4% | n/a | ||
AMYTAmryt Pharma | US$14.70 | 0.7% | 86.5% | US$940.7m | US$20.75 | PS3.9x | E53.9% | n/a | ||
ACERAcer Therapeutics | US$0.80 | -5.4% | -30.0% | US$19.7m | n/a | PE-0.5x | E66.2% | n/a | ||
OTLKOutlook Therapeutics | US$0.41 | -7.4% | -62.8% | US$103.0m | US$2.22 | PE-2x | E62.1% | n/a | ||
UNCYUnicycive Therapeutics | US$1.53 | 8.5% | -5.6% | US$51.1m | US$4.38 | PS78.8x | E59.4% | n/a | ||
RYTMRhythm Pharmaceuticals | US$41.67 | -4.7% | 112.6% | US$2.5b | US$57.22 | PS32.4x | E61.1% | n/a |